II. AMENDMENT TO THE CLAIMS

Claims 1-36 (Previously Cancelled)

Claim 37 (Currently amended) A transdermal delivery system for an opioid analgesic, comprising an opioid agonist and an opioid antagonist contained in a reservoir or matrix and capable of delivery from the system in a controlled manner, such that when the system is applied to the skin of a human patient, the opioid agonist and the opioid antagonist are released at substantially proportionate rates, the opioid agonist is delivered at a mean relative release rate effective to provide analgesia to the patient for at least 3 days, and the opioid antagonist is delivered at a mean relative release rate sufficient to reduce a side effect associated with the opioid agonist, said antagonist selected from the group consisting of naloxone, naltrexone, ~~cyclazacine~~ cyclazocine, levallorphan and pharmaceutically acceptable salts thereof.

Claims 38-39 (Cancelled)

Claim 40. (Previously added) The transdermal delivery system of claim 37, wherein said opioid antagonist comprises naloxone or a pharmaceutically acceptable salt thereof.

Claim 41. (Previously added) The transdermal delivery system of claim 37, wherein said opioid antagonist comprises naltrexone or a pharmaceutically acceptable salt thereof.

Claim 42. (Previously added) The transdermal delivery system of claim 37, wherein said opioid agonist is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene,

fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine, tramadol, mixtures thereof and pharmaceutically acceptable salts thereof.

Claim 43. (Previously added) The transdermal delivery system of claim 42, wherein said opioid agonist comprises fentanyl or a pharmaceutically acceptable salt thereof.

Claim 44. (Previously added) The transdermal delivery system of claim 42, wherein said opioid agonist comprises buprenorphine or a pharmaceutically acceptable salt thereof.

Claim 45. (Previously added) The transdermal delivery system of claim 42, wherein said opioid agonist comprises morphine or a pharmaceutically acceptable salt thereof.

Claim 46. (Previously added) The transdermal delivery system of claim 42, wherein said opioid agonist comprises hydromorphone or a pharmaceutically acceptable salt thereof.

Claim 47. (Previously added) The transdermal delivery system of claim 42, wherein said opioid agonist comprises oxycodone or a pharmaceutically acceptable salt thereof.

Claim 48. (Cancelled)

Claim 49. (Previously added) The transdermal delivery system of claim 37, wherein the opioid antagonist is treated to modify its release rate before it is combined with the opioid agonist, such that when the opioid agonist and the treated antagonist are combined into the

transdermal delivery system, the opioid agonist and antagonist are released from the system at substantially proportionate rates.